^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | zongertinib (BI 1810631) (HER2 exon 20 mutation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1 Trial of BI 1810631, a HER2 Tyrosine Kinase Inhibitor (TKI), as Monotherapy in Patients with Advanced/Metastatic Solid Tumors with HER2 Aberrations
Published date:
01/28/2023
Excerpt:
This phase 1a/1b, open-label, non-randomized study aims to determine...preliminary efficacy of BI 1810631 in patients with HER2 aberration-positive solid tumors (NCT04886804)…. In 23 patients evaluable for response the overall response rate (ORR) was 39% (n=9; NSCLC: n=7; esophagus, cholangiocarcinoma: n=1). The disease control rate (DCR) was 83%.
Trial ID:
